RELATED STUDY
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Key Findings: The evidence available to-date has demonstrated a potentially significant role of cannabinoids in the treatment of dementia for neurodegenerative disorders including: Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD) and vascular dementia (VD).
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Switzerland
Year of Pub: 2019
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Synthetic Cannabinoid (unspecified), Pharma THC
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype I, Chemotype III
Receptors Studied: CB1, CB2
Ligands Studied: Acetylcholine, GABA, Glutamate, Pro-inflammatory cytokines
